'Amgen is close to a deal to acquire Horizon Therapeutics in a transaction worth as much as $20bn, according to sources familiar with the matter, as a sell-off in healthcare stocks creates attractive targets.

(...)

The takeover would give Amgen access to Horizon’s pipeline of drugs for rare autoimmune and inflammatory diseases, including its blockbuster treatment Tepezza.'

#DrugDiscovery #DrugDiscovery #Pharma #Amgen #Autoimmunity #Immunology

https://www.ft.com/content/3cace2fc-406d-496b-9060-0f68e8b93080